Glenmark Pharmaceuticals: Analyst Deven Choksey Reaffirms BUY Rating with INR 2,300 Target Price

Overview

Glenmark Pharmaceuticals reported a significant revenue jump of 76.1% year-on-year to INR 60,469 million, driven by an upfront payment. Analyst Deven Choksey reiterated a "BUY" rating, setting a target price of INR 2,300 based on September 2027 earnings estimates, signaling confidence in the company's future performance.